ArriVent goes Further into PACC mutations
The group is aiming for accelerated approval with the upcoming Alpacca trial.
After Blueprint's takeover comes Cogent's big test
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
Opinion: dealing with failure, iTeos style
When your investment case breaks down, why not just do the decent thing?
Arvinas and 3SBio hope to do better
A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.
DLL3 goes trispecific
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
EHA 2025 – J&J claims an extramedullary edge
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
Lyell takes on J&J and Gilead
The players are vying in the CD19 x CD20 Car-T arena.
EHA 2025 – Incyte puts its foot on the CALR gas
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
NextCure joins Merck in an ovarian target
But the former is paying a fraction of what Merck shelled out for raludotatug.
EHA 2025 – ELVN-001 enlivens investors
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
